Safety of Skin Cleansing With Chlorhexidine in Preterm Low Birth Weight Infants
This study has been completed.
Sponsor:
All India Institute of Medical Sciences, New Delhi
Information provided by:
All India Institute of Medical Sciences, New Delhi
ClinicalTrials.gov Identifier:
NCT00947518
First received: April 20, 2009
Last updated: July 27, 2009
Last verified: June 2009
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Results First Received: April 20, 2009
| Study Type: | Interventional |
|---|---|
| Study Design: | Allocation: Randomized; Endpoint Classification: Safety/Efficacy Study; Intervention Model: Parallel Assignment; Masking: Double Blind (Subject, Investigator, Outcomes Assessor); Primary Purpose: Prevention |
| Conditions: |
Neonatal Sepsis Low Birth Weight |
| Interventions: |
Drug: Chlorhexidine Drug: Normal saline |
Participant Flow
Recruitment Details
| Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations |
|---|
| from August 2005 to February 2006 at the tertiary level neonatal intensive care unit of All India Institute of Medical Sciences, New Delhi |
Pre-Assignment Details
| Significant events and approaches for the overall study following participant enrollment, but prior to group assignment |
|---|
| Infants with one minute Apgar score <4, hemodynamic instability, congenital malformations, generalized skin disorder and who needed respiratory support (continuous positive airway pressure and/or intermittent mandatory ventilation) were excluded |
Reporting Groups
| Description | |
|---|---|
| Chlorhexidine Skin Cleansing | Wiping the skin (except the face) using baby wipes containing 0.25% free chlorhexidine (equivalent to 0.44% chlorhexidine digluconate) |
| Saline Skin Cleansing | Wiping the skin (except the face) using baby wipes containing normal saline |
| No Skin Cleansing | No skin application |
Participant Flow: Overall Study
| Chlorhexidine Skin Cleansing | Saline Skin Cleansing | No Skin Cleansing | |
|---|---|---|---|
| STARTED | 20 | 20 | 20 |
| COMPLETED | 20 | 20 | 20 |
| NOT COMPLETED | 0 | 0 | 0 |
Baseline Characteristics
Reporting Groups
| Description | |
|---|---|
| Chlorhexidine Skin Cleansing | Wiping the skin (except the face) using baby wipes containing 0.25% free chlorhexidine (equivalent to 0.44% chlorhexidine digluconate) |
| Saline Skin Cleansing | Wiping the skin (except the face) using baby wipes containing normal saline |
| No Skin Cleansing | No skin application |
| Total | Total of all reporting groups |
Baseline Measures
| Chlorhexidine Skin Cleansing | Saline Skin Cleansing | No Skin Cleansing | Total | |
|---|---|---|---|---|
|
Number of Participants
[units: participants] |
20 | 20 | 20 | 60 |
|
Age
[units: participants] |
||||
| <=18 years | 20 | 20 | 20 | 60 |
| Between 18 and 65 years | 0 | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 | 0 |
|
Gender
[units: participants] |
||||
| Female | 7 | 11 | 11 | 29 |
| Male | 13 | 9 | 9 | 31 |
|
Gestation (weeks)
[1] [units: weeks] Median ( Full Range ) |
33
( 28 to 36 ) |
33
( 28 to 36 ) |
32.5
( 28 to 36 ) |
33
( 28 to 36 ) |
| [1] | Estimated gestational age in completed weeks |
|---|
Outcome Measures
| 1. Primary: | Median Skin Condition Score on the 9-point Skin Condition Grading Scale Adapted by Darmstadt From Lane et al [ Time Frame: At 24 hours ] |
| 2. Primary: | Skin Temperature at 30 Min After Intervention [ Time Frame: at 30 min after intervention ] |
| 3. Primary: | Number of Participants With Positive Skin Culture at Axilla [ Time Frame: 24 hours after intervention ] |
| 4. Secondary: | Incidence of Clinical and Culture Positive Sepsis [ Time Frame: First week of life. ] |
Results not yet posted. Anticipated Posting Date:
09/2009
Safety Issue:
No
More Information
Certain Agreements:
Limitations and Caveats
Results Point of Contact:
No publications provided
| Principal Investigators are NOT employed by the organization sponsoring the study. |
| There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. |
Limitations and Caveats
| Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data |
|---|
| No text entered. |
Results Point of Contact:
Name/Title: Mari Jeeva Sankar
Organization: Department of Pediatrics, All India Institute of Medical Sciences, New Delhi
phone: +91-11-26594372
e-mail: jeevasankar@gmail.com
Organization: Department of Pediatrics, All India Institute of Medical Sciences, New Delhi
phone: +91-11-26594372
e-mail: jeevasankar@gmail.com
No publications provided
| Responsible Party: | M Jeeva Sankar, Department of Pediatrics, AIIMS, New Delhi |
| ClinicalTrials.gov Identifier: | NCT00947518 History of Changes |
| Other Study ID Numbers: | 10/2004 |
| Study First Received: | April 20, 2009 |
| Results First Received: | April 20, 2009 |
| Last Updated: | July 27, 2009 |
| Health Authority: | India: Institutional Review Board |